The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

January 25, 2021

Nageshwara Arvind Dasari, MD, discusses the potential clinical implications with fruquintinib in metastatic colorectal cancer.

January 21, 2021

William G. Wierda, MD, PhD, discusses the latest CAPTIVATE findings in patients with chronic lymphocytic leukemia.

January 19, 2021

Elias Jabbour, MD, discusses selecting ponatinib after failure of a second-generation TKI therapy in chronic myeloid leukemia.

January 18, 2021

Kanwal Raghav, MBBS, MD, discusses the role of molecular profiling in treatment selection for patients with metastatic colorectal cancer.

January 18, 2021

David S. Hong, MD, discusses the potential clinical implications of the phase 1 SURPASS trial in gastric/gastroesophageal junction cancer.

January 16, 2021

Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, discusses the clinical activity of pralsetinib (Gavreto) in RET fusion-positive pancreatic cancer and cholangiocarcinoma.

January 13, 2021

January 12, 2021

A gene expression signature based on tumor cell lineage/state compositions can predict survival in patients with peritoneal carcinomatosis.

December 29, 2020

Debu Tripathy, MD, discusses strategies that can be used to overcome ESR1 mutations in estrogen receptor–positive breast cancer.

December 24, 2020

Preetesh Jain, MD, PhD, discusses the efficacy of ibrutinib and rituximab in elderly patients with previously untreated mantle cell lymphoma.

December 24, 2020

Hun Ju Lee, MD, discusses responses to cirmtuzumab plus ibrutinib in patients with mantle cell lymphoma.

December 21, 2020

Preetesh Jain, MD, PhD, discusses the role of BTK inhibitors in mantle cell lymphoma.

December 17, 2020

Elias Jabbour, MD, discusses data with asciminib in patients with chronic-phase chronic myeloid leukemia.

December 16, 2020

Srdan Verstovsek, MD, PhD, discusses the role of ruxolitinib in myelofibrosis.

December 16, 2020

December 16, 2020 — The combination of nivolumab with ipilimumab demonstrated activity in patients with metastatic uveal melanoma with encouraging responses.

December 09, 2020

Renata Ferrarotto, MD, discusses trilaciclib’s unique mechanism of action in small cell lung cancer and the data that led to its FDA designation.

December 08, 2020

Hussein A. Tawbi, MD, PhD, discusses future research efforts in melanoma.

December 07, 2020

Preetesh Jain, MD, PhD, discusses the rationale to evaluate ibrutinib in combination with rituximab in mantle cell lymphoma.

December 04, 2020

In a recent OncLive Peer Exchange®, a panel of hematologic experts discusses the paradigm shift in frontline therapy options for patients with CLL.

November 25, 2020

Milind Javle, MD, provides insight into the current treatment paradigm of advanced HCC and the potential influence ongoing research regarding biomarkers of response and novel combinations could have on the field.